Israeli Medtech Firm IceCure Gains FDA Approval for Post-Market Breast Cancer Study
IceCure Medical's ProSense cryoablation, a minimally invasive breast cancer treatment, is now under FDA review in a post-market study called "ChoICE.".
























IceCure Medical's ProSense cryoablation, a minimally invasive breast cancer treatment, is now under FDA review in a post-market study called "ChoICE.".
Israeli scientists identify early DNA "weak spots" that may detect breast cancer years before it starts. This Hebrew University study offers new hope for.
Israeli scientists from Tel Aviv University made a breakthrough, discovering how breast cancer adapts to the brain, paving the way for new treatments for 10-15%.